Turn Therapeutics (TTRX) Return on Assets (2025 - 2026)

Turn Therapeutics' (TTRX) quarterly Return on Assets came in at 0.01% in Q1 2026, up 34.19% quarter-over-quarter from 0.01% in Q4 2025.

Turn Therapeutics (TTRX) Return on Assets (2025 - 2026) Analysis & Trends

Turn Therapeutics' Return on Assets history runs 2 years deep, the most recent figure standing at 0.01% for Q1 2026.

  • On a quarterly basis, Return on Assets changed N/A year-over-year to 0.01% in Q1 2026; TTM through Mar 2026 was 0.01%, a N/A change from a year earlier, with the FY2025 full-year figure at 0.02%, changed N/A from the prior year.
  • Return on Assets rose to 0.01% in Q1 2026 per TTRX's latest filing, from 0.01% in the prior quarter.
  • Across five years, Return on Assets topped out at 0.01% in Q1 2026 and bottomed at 0.01% in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROA (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -0.69%
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 0.00%
4 NuCana 279.75 Bn 279.75 Bn - -0.01%
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 0.00%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 0.00%
7 Belite Bio 62.51 Bn 62.51 Bn - -0.80%
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - 0.00%
10 Turn Therapeutics 282.39 Mn 282.39 Mn - -0.01%

Historic Data

Download Data
DateValue
Mar 31, 2026 -0.01%
Dec 31, 2025 -0.01%